Drug, Medical Device Companies Worry Comparative Effectiveness Research Will Limit Patient Options

Main Category: Pharma Industry / Biotech Industry
Also Included In: Medical Devices / Diagnostics;  Public Health
Article Date: 15 Apr 2009 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Drug and medical device companies, along with some members of Congress, have expressed concern that the $1.1 billion for comparative effectiveness research included in the economic stimulus package will yield findings that could be used to limit patients' options, the Wall Street Journal reports.

As part of the stimulus package, NIH and HHS are each set to receive $400 million and the Agency for Healthcare Research and Quality is set to receive $300 million for conducting research comparing the effectiveness of different treatment options as a means to reduce use of wasteful and ineffective treatments. HHS has established an advisory committee to coordinate research and distribute the funds; the committee will hold a meeting on Tuesday to gather public input on how the funds for HHS should be spent. NIH has noted that it will consider funding research that aims to compare the cost-effectiveness of biologic drugs, cancer treatments and preventive measures for chronic diseases.

However, Lori Reilly, vice president for policy and research at the Pharmaceutical Research and Manufacturers of America, said, "We don't want (the research) to be used to deny access to care." Teresa Lee, vice president of the Advanced Medical Technology Association, said using "this research to deny access to appropriate treatments for individual patients with individual medical histories and individual needs should not be the objective." Carolyn Clancy, director of AHRQ, said that "the overarching purpose of the program is to give clinicians and patients information on effectiveness, safety and costs" (Zhang, Wall Street Journal, 4/14).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Drug, Medical Device Companies Worry Comparative Effectiveness Research Will Limit Patient Options." Medical News Today. MediLexicon, Intl., 15 Apr. 2009. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/146103.php>

APA
Kaiser. (2009, April 15). "Drug, Medical Device Companies Worry Comparative Effectiveness Research Will Limit Patient Options." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/146103.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »